WO2020218941A1 - Tadalafil synthesis method - Google Patents

Tadalafil synthesis method Download PDF

Info

Publication number
WO2020218941A1
WO2020218941A1 PCT/RU2019/000529 RU2019000529W WO2020218941A1 WO 2020218941 A1 WO2020218941 A1 WO 2020218941A1 RU 2019000529 W RU2019000529 W RU 2019000529W WO 2020218941 A1 WO2020218941 A1 WO 2020218941A1
Authority
WO
WIPO (PCT)
Prior art keywords
product
flow
tadalafil
synthesis
millireactor
Prior art date
Application number
PCT/RU2019/000529
Other languages
English (en)
French (fr)
Inventor
Igor Niсkolaevich TARASOV
Farid Minikasimovich IBATULLIN
Original Assignee
Obshestvo S Ogranichennoy Otvetstvennostuy "Baltfarma"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obshestvo S Ogranichennoy Otvetstvennostuy "Baltfarma" filed Critical Obshestvo S Ogranichennoy Otvetstvennostuy "Baltfarma"
Publication of WO2020218941A1 publication Critical patent/WO2020218941A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Definitions

  • the invention relates to a continuous method for the synthesis of tadalafil from methyl ( 1 R,3R)- 1 -( 1 ,3 -benzodioxol-5 -y l)-2 ,3 ,4,9-tetrahydro-2-chloroacetyl- 1 H-pyrido [3 ,4-b] indole-3 - carboxy late .
  • Tadalafil is an effective reversible selective inhibitor of specific phosphodiesterase type 5 (PDE5) of cyclic guanosine monophosphate (cGMP). It was first developed by GlaxoSmithKline (GSK) and approved by FDA in 2003 for the treatment of erectile dysfunction (ED) in men.
  • PDE5 specific phosphodiesterase type 5
  • cGMP cyclic guanosine monophosphate
  • Erectile dysfunction is the inability to develop and/or maintain an erection sufficient during sexual activity.
  • ED remains an important social and medical problem all over the world, and not only the condition of the working male population, but also the general family and social level depends on its solution. Therefore, taking into account the social status of the problem, this problem should be attributed to socially significant ones that require affordable medical care for all social groups of the population.
  • Tadalafil was also approved by FDA in 2006 for the treatment of pulmonary arterial hypertension, and therefore, the need in a greater amount of the substance arose.
  • Tadalafil (CAS 171596-29-5) is known as (6R, 12aR)-6-(1,3-benzodioxol-5- yl)-2,3,6,7, 12, 12a-hexahydro-2-methylpyrazino[1',2': 1 ,6]pyrido [3, 4-b] indole- 1 ,4- dione, and its chemical structure is presented below:
  • tadalafil is synthesised from crystals of methyl (lR,3R)-l-(l,3-benzodioxol-5-yl)-2-(chloroacetyl)-2,3,4,9-tetrahydro-lH- pyrido[3,4-b]indole-3-carboxylate using tetrahydrofuran (THF) as a solvent with addition of an aqueous solution of methylamine.
  • THF tetrahydrofuran
  • the new continuous method of obtaining tadalafil proposed by us will allow making synthesis of the product without hard-to-remove impurities, with stable quality and yield in a much shorter time at a lower temperature regardless of the weight of the lot.
  • the aim of the invention is to obtain tadalafil (I) in a continuous manner in a flow reactor from methyl (lR,3R)-l-(l,3-benzodioxol-5-yl)-2- (chloroacetyl)-2,3,4,9-tetrahydro-lH-pyrido[3,4-b]indole-3-carboxylate in a short time of reaction.
  • Another feature of this invention is the possibility of using flow reactors, preferably micro- or millireactors, for continuous production of tadalafil.
  • continuous and continuous method means that production processes are carried out in such a way that the supply of raw materials and the isolation of final products during these processes are carried out continuously or in portions without stopping the operation of the system as a whole. All stages of such a process at each point of the apparatus are carried out under the same conditions, which are unchanged for this point.
  • the process of synthesis of tadalafil (I) is a continuous feed of the starting material - a solution of methyl (1R,3R)-1-(1 ,3- benzodioxol-5-yl)-2-(chloroacetyl)-2, 3 ,4,9-tetrahydro- lH-pyrido[3,4-b]indole-3- carboxylate (II) in an aprotic solvent and methylamine to the reactor at constant flow rates, temperature and pressure.
  • the reaction time determined by the time of passage of the entire reactor volume remains constant.
  • flow reactor means a reactor, in which the synthesis is possible in a continuous pattern, where all technological operations take place simultaneously.
  • microreactor and “millireactor” mean a flow reactor characterized by high speed of mass transfer and heat transfer, with a small internal volume and small channel size, which allows working in a continuous mode, taking into account the constant parameters of the process over time and the possibility of its full automation. Intensive heat removal and heat transfer from the walls of the micro- and millireactor is explained by the large area of the channel with respect to its small internal volume, and therefore it is possible to conduct exothermic and endothermic reactions in such reactors under conditions that are nearly isothermal.
  • Microreactors include flow reactors with an internal diameter/channel size in the range from 10-100 mm to 1 mm.
  • the millireactors include flow reactors with an internal diameter/channel size in the range from 1 to 10 mm.
  • the cross section of the micro- and milli-channel can be round, rectangular, and other shapes, while the channel can contain built-in static stirrers both along its entire length and only on one part of it, and the channel can also be made without static stirrers.
  • Thermostating of reactors can be carried out using a liquid thermostat or using electrically heated elements, depending on the conditions of the reaction, the required temperature range and heat removal requirements.
  • the invention proposes a continuous method for the production of tadalafil from methyl ( 1 R,3R)- 1 -( 1 ,3-benzodioxol-5-yl)-2-(chloroacetyl)-2,3 ,4,9-tetrahydro- 1 H-pyrido [3, 4-b] indole-3 -carboxylate (II).
  • a solution of methyl (lR,3R)-l-(l,3-benzodioxol-5-yl)-2- (chloroacetyl)-2,3,4,9-tetrahydro-lH-pyrido[3,4-b]indole-3-carboxylate (II) in an aprotic solvent is used as an initial solution in vessel V-l (Fig. 1 and 2).
  • Methylamine a solution of methylamine or an aqueous solution of methylamine, preferably an aqueous solution of methylamine, is used as the starting reagent.
  • the use of methylamine solution in the vessel for reagents V-2 is shown in Figure 1.
  • the use of gaseous methylamine in the flask B is shown in Figure 2.
  • Dimethylformamide, N-methylpyrrolidone or dimethyl sulfoxide, preferably dimethylformamide, is used as an aprotic solvent.
  • the flow rates for the initial solution and reagent for pumps P-1 and P-2 are selected on the basis of the reaction time and are indicated in specific examples.
  • the flow rates of the initial solution and gaseous methylamine are selected based on the time of the reaction and are indicated in specific examples.
  • the operating time, the weight of the resulting product are particular cases for the continuous synthesis and are indicated in specific examples.
  • Methylamine was used at stage 2 as the base which catalyzed the cyclization reaction by feeding it to the micro- or millireactor in excess at stage 1.
  • the selection of reagents used in the invention and their concentrations allow using only two pumps and one micro- or millireactor in the continuous method of the production of tadalafil without the need for an additional supply of reagents at stage 2.
  • the reaction was carried out using the isothermal method at a temperature selected for stages 1 and 2.
  • the total reaction time at stages 1 and 2 in the micro- or millireactor is from 1 to 60 minutes, preferably from 2 to 20 minutes, even more preferably from 3 to 4.5 minutes.
  • the pressure range used in the micro- or millireactor is from 1 to 40 bar, preferably in the range from 3 to 10 bar.
  • Figure 1 presents a schematic view of the micro- or millireactor installation, which includes vessels V-l and V-2 for the initial solutions, pumps P-1 and P-2 for supplying these solutions, micro- or millireactor R, vessel V-3 for collecting the product.
  • Syringe pumps with two syringes connected via a T-shaped mixer were used as pumps. Pump heads and syringes are made of materials resistant to corrosion.
  • the micro- or millireactor R is made of Hastelloy, which is one of the most corrosion resistant alloys. Flows mixing occurs inside the micro- or millireactor.
  • any commercially available micro- or millireactor can be used, in which reactions can be carried out in specified ranges of time, temperature and pressure.
  • Figure 2 presents a schematic view of the micro- or millireactor installation, which includes a vessel V-l for the initial solution, a pump P for supplying this solution, a micro- or millireactor R, a cylinder with gaseous methylamine B, a gas flow regulator FC, a vessel V-2 for collecting the product.
  • a syringe pump with two syringes connected via a T-shaped mixer was used as a pump. Pump heads and syringes are made of materials resistant to corrosion.
  • the micro- or millireactor R is made of Hastelloy, which is one of the most corrosion-resistant alloys, the flows mixing occurs inside the micro- or millireactor.
  • any commercially available micro- or millireactor can be used, in which reactions can be carried out in specified ranges of time, temperature and pressure.
  • Flow 1 is created by the pump P-1, the flow rate is 7.5 ml/min.
  • Flows 1 and 2 are fed into the millireactor and mixed directly in the millireactor.
  • the temperature of the reaction mixture is maintained at 40 °C, the isothermal synthesis is carried out during the entire time of production. Thermostating is carried out by a liquid thermostat.
  • the pressure in the millireactor is 8 bar.
  • the exposure time of the reaction mixture in the millireactor was 3 min 42 sec.
  • the product was collected at the outlet of the millireactor into the collector at room temperature, simultaneously a flow of methanol was added to the product stream at the rate of 30 ml/min, and the mixture was stirred at room temperature. After the end of the lot production, the mixture was fed to the Schott filter, the product was separated on the filter, after washing the product it was dried to constant weight, the mother liquor was collected and subjected to additional purification/evaporation to isolate the product residue.
  • Flow 1 is created by the pump P-1, the flow rate is 7.5 ml/min.
  • Flows 1 and 2 are fed into the millireactor and mixed directly in the millireactor.
  • the temperature of the reaction mixture is maintained at 35 °C, the isothermal synthesis is carried out during the entire time of production. Thermostating is carried out by a liquid thermostat.
  • the pressure in the millireactor is 8 bar.
  • the exposure time of the reaction mixture in the millireactor was 3 min 42 sec.
  • the product was collected at the outlet of the millireactor in the collector at room temperature. After collecting the product for 1 hour, methanol was added to the product in the collector. The volume ratio of methanol to the collected product solution comprised 4: 1, the mixture was stirred for 1 hour. The mixture was fed to the Schott filter, the product was separated on the filter, after washing the product it was dried to constant weight, the mother liquor was collected and subjected to additional purification/evaporation to isolate the product residue.
  • Flow 1 is created by the pump P-1, the flow rate is 6.25 ml/min.
  • Flows 1 and 2 are fed to the millireactor and are stirred there.
  • the temperature of the reaction mixture is maintained at 40 °C, the isothermal synthesis is carried out during the entire time of production. Thermostating is carried out by a liquid thermostat.
  • the pressure is 3 bar.
  • the exposure time of the reaction mixture in millireactor is 4 min 18 sec.
  • the product was collected at the outlet from the millireactor into the collector at room temperature, Flow 3 of methanol was simultaneously added to the product flow at the rate of 24 ml/min, the mixture was stirred at room temperature, then the mixture was fed to the Schott filter, the product was separated on the filter, after washing the product it was dried to constant weight, the mother liquor was collected and subjected to additional purification/evaporation to isolate residues of the product.
  • Flow 1 is created by the pump P- 1 , the flow rate is 7.5 ml/min.
  • Flows 1 and 2 are fed into the millireactor and mixed directly in the millireactor.
  • the temperature of the reaction mixture is maintained at 30 °C, the isothermal synthesis is carried out during the entire time of production. Thermostating is carried out by a liquid thermostat.
  • the pressure in the millireactor is 12 bar.
  • the exposure time of the reaction mixture in the millireactor was 3 min 42 sec.
  • the product was collected at the outlet of the millireactor in the collector at room temperature, at the same time methanol was added to the product flow, and the mixture was stirred at room temperature. After the end of the lot production, the mixture was fed to the Schott filter, the product was separated on the filter, after washing the product it was dried to constant weight, the mother liquor was collected and subjected to additional purification/evaporation to isolate the product residue.
  • Flow 1 is created by the pump P-1, the flow rate is 3.75 ml/min.
  • Flow 2 is created by the pump P-2, the flow rate is 0.85 ml/min.
  • Flows 1 and 2 are fed into the microreactor and mixed directly in the microreactor.
  • the temperature of the reaction mixture is maintained at 35 °C, the isothermal synthesis is carried out during the entire time of production. Thermostating is carried out by a liquid thermostat.
  • the pressure in the microreactor is 2.5 bar.
  • the exposure time of the reaction mixture in the microreactor was 1 min 44 sec.
  • the product was collected at the outlet of the microreactor in the collector at room temperature, at the same time methanol was added to the product flow, and the mixture was stirred at room temperature. After the end of the lot production, the mixture was fed to the Schott filter, the product was separated on the filter, after washing the product it was dried to constant weight, the mother liquor was collected and subjected to additional purification/evaporation to isolate the product residue.
  • Flow 1 is created by the pump P-1, the flow rate is 1.8 ml/min.
  • Flows 1 and 2 are fed into the microreactor and mixed directly in the microreactor.
  • the temperature of the reaction mixture is maintained at 40 °C, the isothermal synthesis is carried out during the entire time of production. Thermostating is carried out by a liquid thermostat.
  • the pressure in the microreactor is 3.5 bar.
  • the exposure time of the reaction mixture in the microreactor was 3 min 28 sec.
  • the product was collected at the outlet of the microreactor in the collector at room temperature, at the same time methanol flow was added to the product flow, and the mixture was stirred at room temperature. After the end of the lot production, the mixture was fed to the Schott filter, the product was separated on the filter, after washing the product it was dried to constant weight, the mother liquor was collected and subjected to additional purification/evaporation to isolate the product residue.
  • Flow 1 is created by the pump P-1, the flow rate is 2.5 ml/min.
  • Flows 1 and 2 are fed into the microreactor and mixed directly in the microreactor.
  • the temperature of the reaction mixture is maintained at 35 °C, the isothermal synthesis is carried out during the entire time of production. Thermostating is carried out by a liquid thermostat.
  • the pressure in the microreactor is 2.5 bar.
  • the exposure time of the reaction mixture in the microreactor was 2 min 36 sec.
  • the product was collected at the outlet of the microreactor in the collector at room temperature, at the same time methanol was added to the product flow, and the mixture was stirred at room temperature. After the end of the lot production, the mixture was fed to the Schott filter, the product was separated on the filter, after washing the product it was dried to constant weight, the mother liquor was collected and subjected to additional purification/evaporation to isolate the product residue.
  • Flow 1 is created by the pump P-1, the flow rate is 2.5 ml/min.
  • Flows 1 and 2 are fed into the microreactor and mixed directly in the microreactor.
  • the temperature of the reaction mixture is maintained at 35 °C, the isothermal synthesis is carried out during the entire time of production. Thermostating is carried out by a liquid thermostat.
  • the pressure in the microreactor is 2.5 bar.
  • the exposure time of the reaction mixture in the microreactor was 2 min 36 sec.
  • the product was collected at the outlet of the microreactor in the collector at room temperature, at the same time methanol was added to the product flow, and the mixture was stirred at room temperature. After the end of the lot production, the mixture was fed to the Schott filter, the product was separated on the filter, after washing the product it was dried to constant weight, the mother liquor was collected and subjected to additional purification/evaporation to isolate the product residue.
  • the temperature of the reaction mixture is maintained at 35 °C, the isothermal synthesis is carried out during the entire time of production. Thermostating is carried out by a liquid thermostat.
  • the exposure time of the reaction mixture in millireactor is 4 min 30 sec. Flows 1 and 2 were fed to the millireactor for 1 hour and collected in the collector V-3.
  • the product was collected at the outlet of the millireactor in the collector at room temperature. After collecting the product for 1 hour, methanol was added to the product in the collector. The volume ratio of methanol to the collected product solution comprised 4: 1, the mixture was stirred for 1 hour. The mixture was fed to the Schott filter, the product was separated on the filter, after washing the product it was dried to constant weight, the mother liquor was collected and subjected to additional purification/evaporation to isolate the product residue.
  • the temperature of the reaction mixture is maintained at 40 °C, the isothermal synthesis is carried out during the entire time of production. Thermostating is carried out by a liquid thermostat.
  • the exposure time of the reaction mixture in the microreactor was 3 min 12 sec.
  • the product was collected at the outlet of the microreactor in the collector at room temperature. After collecting the product for 1 hour, methanol was added to the product in the collector. The volume ratio of methanol to the collected product solution comprised 4:1, the mixture was stirred for 1 hour. The mixture was fed to the Schott filter, the product was separated on the filter, after washing the product it was dried to constant weight, the mother liquor was collected and subjected to additional purification/evaporation to isolate the product residue.
  • Flow 1 is created by the pump P-1, the flow rate is 0.83 ml/min.
  • Flow 2 is created by the pump P-2, the flow rate is 0.19 ml/min.
  • Flows 1 and 2 are fed into the millireactor and mixed directly in the millireactor.
  • the temperature of the reaction mixture is maintained at 32 °C, the isothermal synthesis is carried out during the entire time of production. Thermostating is carried out by a liquid thermostat.
  • the pressure in the millireactor is 7 bar.
  • the exposure time of the reaction mixture in millireactor is 33 min 18 sec.
  • the product was collected at the outlet of the millireactor in the collector at room temperature, at the same time methanol was added to the product flow, and the mixture was stirred at room temperature. After the end of the lot production, the mixture was fed to the Schott filter, the product was separated on the filter, after washing the product it was dried to constant weight, the mother liquor was collected and subjected to additional purification/evaporation to isolate the product residue.
  • Flow 1 is created by the pump P-1, the flow rate is 2.5 ml/min.
  • Flows 1 and 2 are fed into the microreactor and mixed directly in the microreactor.
  • the temperature of the reaction mixture is maintained at 40 °C, the isothermal synthesis is carried out during the entire time of production. Thermostating is carried out by a liquid thermostat.
  • the pressure in the microreactor is 2.8 bar.
  • the exposure time of the reaction mixture in the microreactor was 2 min 36 sec.
  • the product was collected at the outlet of the microreactor in the collector at room temperature, at the same time methanol was added to the product flow, and the mixture was stirred at room temperature. After the end of the lot production, the mixture was fed to the Schott filter, the product was separated on the filter, after washing the product it was dried to constant weight, the mother liquor was collected and subjected to additional purification/evaporation to isolate the product residue.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PCT/RU2019/000529 2019-04-26 2019-07-29 Tadalafil synthesis method WO2020218941A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2019112922 2019-04-26
RU2019112922A RU2692764C1 (ru) 2019-04-26 2019-04-26 Способ получения тадалафила

Publications (1)

Publication Number Publication Date
WO2020218941A1 true WO2020218941A1 (en) 2020-10-29

Family

ID=67038352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2019/000529 WO2020218941A1 (en) 2019-04-26 2019-07-29 Tadalafil synthesis method

Country Status (2)

Country Link
RU (1) RU2692764C1 (ru)
WO (1) WO2020218941A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2692764C1 (ru) * 2019-04-26 2019-06-27 Общество с ограниченной ответственностью "Балтфарма" Способ получения тадалафила

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019978A1 (en) 1994-01-21 1995-07-27 Laboratoires Glaxo Wellcome S.A. Tetracyclic derivatives, process of preparation and use
WO2005068464A2 (en) 2003-12-15 2005-07-28 Cadila Healthcare Limited Process for preparing tadalafil and its intermediates
WO2009144734A1 (en) 2008-05-28 2009-12-03 Hetero Research Foundation Process for preparation of tadalafil
CN103980275A (zh) 2014-05-14 2014-08-13 湖北省医药工业研究院有限公司 磷酸二酯酶5抑制剂他达拉非的制备方法
WO2014183730A2 (zh) * 2013-05-14 2014-11-20 张家港威胜生物医药有限公司 一种他达那非的制备方法
WO2016012539A1 (en) * 2014-07-23 2016-01-28 Krka, D.D., Novo Mesto A process for the preparation of cgmp-phosphodiesterase inhibitor and oral pharmaceutical formulation comprising tadalafil co-precipitates
CN105384740A (zh) 2015-12-18 2016-03-09 海南通用康力制药有限公司 一种制备他达拉非的中间体高纯度晶体及制备方法
CN107973796A (zh) * 2017-12-08 2018-05-01 珠海联邦制药股份有限公司 一种他达拉非异构体的制备方法
RU2692764C1 (ru) * 2019-04-26 2019-06-27 Общество с ограниченной ответственностью "Балтфарма" Способ получения тадалафила

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019978A1 (en) 1994-01-21 1995-07-27 Laboratoires Glaxo Wellcome S.A. Tetracyclic derivatives, process of preparation and use
WO2005068464A2 (en) 2003-12-15 2005-07-28 Cadila Healthcare Limited Process for preparing tadalafil and its intermediates
WO2009144734A1 (en) 2008-05-28 2009-12-03 Hetero Research Foundation Process for preparation of tadalafil
WO2014183730A2 (zh) * 2013-05-14 2014-11-20 张家港威胜生物医药有限公司 一种他达那非的制备方法
CN103980275A (zh) 2014-05-14 2014-08-13 湖北省医药工业研究院有限公司 磷酸二酯酶5抑制剂他达拉非的制备方法
WO2016012539A1 (en) * 2014-07-23 2016-01-28 Krka, D.D., Novo Mesto A process for the preparation of cgmp-phosphodiesterase inhibitor and oral pharmaceutical formulation comprising tadalafil co-precipitates
CN105384740A (zh) 2015-12-18 2016-03-09 海南通用康力制药有限公司 一种制备他达拉非的中间体高纯度晶体及制备方法
CN107973796A (zh) * 2017-12-08 2018-05-01 珠海联邦制药股份有限公司 一种他达拉非异构体的制备方法
RU2692764C1 (ru) * 2019-04-26 2019-06-27 Общество с ограниченной ответственностью "Балтфарма" Способ получения тадалафила

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 171596-29-5
NEAL G. ANDERSON: "Practical Use of Continuous Processing in Developing and Scaling Up Laboratory Processes", ORGANIC PROCESS RESEARCH AND DEVELOPMENT, vol. 5, no. 6, 1 November 2001 (2001-11-01), US, pages 613 - 621, XP055468733, ISSN: 1083-6160, DOI: 10.1021/op0100605 *

Also Published As

Publication number Publication date
RU2692764C1 (ru) 2019-06-27

Similar Documents

Publication Publication Date Title
CN103980275B (zh) 磷酸二酯酶5抑制剂他达拉非的制备方法
CN111527064B (zh) 有机材料或与其相关的改善
JP2009515695A (ja) 連続流動式反応装置
EP3150572A1 (en) Production method for gamma, delta-unsaturated alcohols
CN104447246A (zh) 一种微反应装置制备邻甲氧基苯甲醛的方法
WO2020218941A1 (en) Tadalafil synthesis method
CN108610293B (zh) 一种采用微通道反应装置制备多韦替尼中间体的方法
Yokosaka et al. An acid-promoted novel skeletal rearrangement initiated by intramolecular ipso-Friedel–Crafts-type addition to 3-alkylidene indolenium cations
CN113307766B (zh) 一种利用微通道反应装置合成吡啶类化合物的方法
CN108276414B (zh) 一种枸橼酸托法替尼的制备方法
CN113181850A (zh) 一种吲哚类化合物的微通道制备方法
CN105731401B (zh) 一种生产盐酸羟胺的方法
CN105524062B (zh) 他达拉非的合成方法
Baumann Integrating reactive distillation with continuous flow processing
CN106632424A (zh) 以1‑(2‑吡啶)‑9‑苄基‑β‑咔啉为配体的氯化铜配合物及其合成方法和应用
CN106397227A (zh) 一种达泊西汀盐酸盐的制备方法
CN110117255A (zh) 一种乐伐替尼杂质及其制备方法
CN100427460C (zh) 一种l-正缬氨酸的合成方法
CN101638406A (zh) 邻-羟甲基苯甲酸内酯的制备方法
CN110437278B (zh) 连续氧化制备草甘膦的方法
CN104211652B (zh) 一种制备普乐沙福的方法
RU2728555C1 (ru) Способ получения этравирина
CN112047942A (zh) 一种7-氟咪唑并[1,2-a]吡啶的合成方法
WO2010049500A2 (en) A process for the preparation of tadalafil.
CN105541840B (zh) 关键中间体及其合成方法和在制备他达拉非方面的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19813195

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19813195

Country of ref document: EP

Kind code of ref document: A1